Today’s Rating On Watch: Wells Fargo: Time To Decrease Faith In Advanced Accelerator (NASDAQ:AAAP)

November 30, 2016 - By Dolores Ford

Today's Rating On Watch: Wells Fargo: Time To Decrease Faith In Advanced Accelerator (NASDAQ:AAAP)

Advanced Accelerator (NASDAQ:AAAP) Downgrade

Advanced Accelerator (NASDAQ:AAAP) was decreased by Wells Fargo from a Outperform rating to a Market Perform rating in a a note released on 29 November.

Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) Ratings Coverage

Out of 5 analysts covering Advanced Accelerator (NASDAQ:AAAP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $44 is the highest target while $32 is the lowest. The $38 average target is 29.38% above today’s ($29.37) stock price. Advanced Accelerator has been the topic of 5 analyst reports since December 7, 2015 according to StockzIntelligence Inc. The stock of Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) has “Market Perform” rating given on Tuesday, November 29 by Wells Fargo. The stock of Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) has “Buy” rating given on Monday, December 7 by Canaccord Genuity. JMP Securities initiated the stock with “Outperform” rating in Monday, December 7 report. Citigroup initiated it with “Neutral” rating and $32 target price in Monday, December 7 report. The firm has “Buy” rating given on Monday, December 7 by Jefferies.

The stock decreased 3.39% or $1.03 during the last trading session, hitting $29.37. Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) has declined 14.60% since April 27, 2016 and is downtrending. It has underperformed by 19.82% the S&P500.

Analysts await Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) to report earnings on December, 8. They expect $-0.09 earnings per share, down 28.57% or $0.02 from last year’s $-0.07 per share. After $-0.04 actual earnings per share reported by Advanced Accelerator Application SA(ADR) for the previous quarter, Wall Street now forecasts 125.00% negative EPS growth.

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company has a market cap of $1.04 billion. The Firm develops, produces and commercializes molecular nuclear medicine , diagnostic and therapeutic products. It currently has negative earnings. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.”

AAAP Company Profile

Advanced Accelerator Applications S.A., incorporated on March 1, 2002, is a radiopharmaceutical company. The Firm develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Firm is engaged in developing its therapeutic candidate, Lutathera, which is a compound for the treatment of neuro endocrine tumors (NETs). It has a portfolio of approximately six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. The Company’s products in clinical development include Lutathera, Somakit and Annexin V-128. The Company’s commercial products include Gluscan/Gluscan 500/Barnascan, IASOflu, IASOdopa, DOPAVIEW, IASOcholine, AAACholine, MIBITEC/Adamibi and Leukokit.

More notable recent Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on January 31, 2015, also Nasdaq.com with their article: “Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy …” published on November 28, 2016, Benzinga.com published: “Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro …” on November 28, 2016. More interesting news about Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) were released by: Benzinga.com and their article: “12 Biggest Mid-Day Losers For Monday” published on November 28, 2016 as well as Schaeffersresearch.com‘s news article titled: “Dow Jones Industrial Average Pulls Back On Cyber Monday” with publication date: November 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>